On the filings, Amgen (AMGN) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it HOLD.
Humira cliff cleared — revenue reaccelerating to +9% and $19B cash flow fund a rich dividend, but the price is full.
Cash-generative, deleveraging biopharma growing ~10% at a fair its multiple — but heavy debt and Repatha patent risk cap upside.
| Metric | ABBV | AMGN |
|---|---|---|
| Fundamentals score | 58 | 84 |
| Revenue growth (YoY) | +8.6% | +10.0% |
| Net income growth (YoY) | -1.2% | +88.5% |
| Net margin | 6.9% | 21.0% |
| Return on equity | — | 89.1% |
| ROIC (est.) | — | 11.3% |
| Liabilities / Equity | — | — |
| Piotroski F-score | 6 / 9 | 6 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 6, 2026, 9:31 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 18, 2026, 7:11 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.